UPLIZNA
PeakmAbinebilizumab
BLAINJECTIONINJECTABLE
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
10
Intelligence
4/8 — Good Coverage
UPLIZNA (inebilizumab) is cd19-directed antibody interactions [moa]. First approved in 2020.
Mechanism of Action
CD19-directed Antibody Interactions
Pharmacologic Class:
CD19-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Started Apr 2026
15 enrolled
Generalized Myasthenia Gravis
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
Started Apr 2026
60 enrolled
Neuromyelitis Optica Spectrum DisorderPregnancy Related
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
Started Apr 2026
15 enrolled
Immunoglobulin G4-related Disease
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Started Jul 2025
220 enrolled
Systemic Lupus ErythematosusActive Refractory Rheumatoid Arthritis
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Started Apr 2024
32 enrolled
Neuromyelitis Optica Spectrum Disorder
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.